Document is current

Article History

Received: 23 January 2024

Accepted: 29 March 2024

First Online: 13 April 2024

Declarations

:

: The study protocol was approved by a Scientific Committee, consisting of external experts, the cooperating sickness funds, the research sponsor, Cytel and IPAM. As the study analyzed retrospective anonymized claims data, the use of such data is not subject to ethics committee approval and no informed consent was required according to German laws (§ 75 SGB X, Tenth Social Code Book). The work on the dataset conformed to all social security data protection requirements. The study followed all the dictates of the Declaration of Helsinki.

: Not applicable.

: JL and NP participated in this study as staff members of Cytel; the work of IPAM and Cytel in this study was funded by Daiichi Sankyo Deutschland GmbH. ML, JH, BM participated in this study as staff members of Daiichi Sankyo Deutschland GmbH. YX participated in this study as staff member of Daiichi Sankyo. TG participated in this study as medical consultant. He is employed at Krankenhaus Nordwest gGmbH and holds a position at IKF- Institut für Klinische Krebsforschung GmbH. TG has provided consultation or served as a consultant for the following companies: Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, FoundationMedicine, Lilly, MCI, MSD Sharp & Dohme, Novartis, Roche, Sanofi Aventis, Servier, Deciphera, Boehringer-Ingelheim. TG has received honorarium from the following companies: Amgen, BMS, Lilly, MSD, Novartis, Sanofi Aventis, Servier, Roche, GSK. He has received funding for scientific investigations from the following sources: Lilly, AstraZeneca, Incyte, German Research Foundation (DFG), Gemeinsamer Bundesausschuss, German Cancer Aid (Deutsche Krebshilfe), Servier. TG has financial relationships with the following companies: Amgen, AstraZeneca, BMS, Lilly, Merck Serono, Roche, Sanofi Aventis, Servier, Pierre-Fabre.